EF24 |
|
Catalog No.GC64496
|
EF24는 새로운 합성 커큐민 유사체이다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 342808-40-6
Sample solution is provided at 25 µL, 10mM.
EF24는 새로운 합성 커큐민 유사체이다. EF24는 산화환원에 의존적으로 기전을 통해 암세포의 사멸을 유도한다[2]. EF24는 항종양 및 노화 방지 효과가 있다[3-4].
A549 세포에서 EF24 (0μM, 0.5μM, 1μM, 2μM, 4μM, 8μM, 16μM; 24시간, 48시간)은NSCLC 세포의 성장을 체외 실험에서 억제한다[5]. K562 세포에서 EF24 (2μM; 24시간)은 백혈병 세포 라인에서 강력한 세포 살상 활성을 보인다[6]. SKOV-3 세포에서 EF24 (3μM; 48시간) 처리는 난소암 세포의 증식과 전이를 감소시킨다[7].
피하HCC 종양 쥐 모델에서 EF24 (20 mg/kg; 복강 주사; 21일)은 종양 성장을 억제하고 세포 사멸을 유도하였다[8]. C57/BL6 쥐에서 EF24 (200 μg/kg; 복강 주사; 14일)은 적외선 조사 후 원격 폐 조직에서 JunB, JunC 및 JunD 수준의 유의한 증가를 현저하게 억제하였다[9]. DU145 피하 종양 쥐 모델에서 EF24 (200 μg/kg; 복강 주사; 4주) 치료는 종양 성장을 현저하게 지연시켰다[10].
References:
[1]. He Y, Li W, Hu G, et al. Bioactivities of EF24, a novel curcumin analog: a review. Frontiers in Oncology. 2018 Dec 11; 8: 614.
[2]. Adams BK, Cai J, Armstrong J, et al. EF24, a novel synthetic curcumin analog, induces apoptosis in cancer cells via a redox-dependent mechanism. Anti-cancer drugs. 2005 Mar 1;16(3):263-275.
[3]. Sazdova I, Keremidarska-Markova M, Dimitrova D, et al. Anticarcinogenic potency of EF24: An overview of its pharmacokinetics, efficacy, mechanism of action, and nanoformulation for drug delivery. Cancers. 2023 Nov 20; 15(22): 5478.
[4]. Li W, He Y, Zhang R, et al. The curcumin analog EF24 is a novel senolytic agent. Aging (Albany NY). 2019 Jan 28;11(2):771.
[5]. Chang M, Shang M, Yuan F, et al. EF24 exerts cytotoxicity against NSCLC via inducing ROS accumulation. Cancer Cell International. 2021 Dec; 21: 1-3.
[6]. Singh AP, Wax N, Duncan J, et al. Genomic Discovery of EF-24 Targets Unveils Antitumorigenic Mechanisms in Leukemia Cells. bioRxiv. 2024 Oct 16: 2024-2010.
[7]. Zhang D, Wang Y, Dong L, et al. Therapeutic role of EF 24 targeting glucose transporter 1‐mediated metabolism and metastasis in ovarian cancer cells. Cancer science. 2013 Dec; 104(12): 1690-1696.
[8]. Liu H, Liang Y, Wang L, et al. In vivo and in vitro suppression of hepatocellular carcinoma by EF24, a curcumin analog. PloS one. 2012 Oct 31; 7(10): e48075.
[9]. Veeraraghavan J, Natarajan M, Awasthi V, et al. EF24, a novel curcumin analogue inhibits oncogenic activation induced by radiation abscopal effect in distant mice lungs. Cancer Research. 2011 Apr 15;71(8_Supplement):4203.
[10]. Yang CH, Yue J, Sims M, et al. The curcumin analog EF24 targets NF-κB and miRNA-21, and has potent anticancer activity in vitro and in vivo. PloS one. 2013 Aug 7; 8(8): e71130.
| 세포 실험 [1]: | |
세포 라인 | A549 세포 |
제조 방법 | 세포 성장/생존력 (MTT) 실험을 위해 A549 세포를 표준 96웰 판에 4000개의 세포로 파종하고 부착을 보장하기 위해 24시간 동안 성장하도록 했습니다. 그리고 성장 배지를 최종 농도가 0μM, 0.5μM, 1μM, 2μM, 4μM, 8μM, 16μM인 EF24를 포함한 배지로 교체했습니다. |
반응 조건 | 0μM, 0.5μM, 1μM, 2μM, 4μM, 8μM, 16μM; 24 시간, 48 시간 |
응용 분야 | EF24는NSCLC세포의 체외 성장을 억제합니다. |
| 동물 실험 [2]: | |
동물 모형 | 피하HCC 종양 쥐 모델 |
제조 방법 | 약 2×10⁶개의 Hepa1-6 세포를 200µL PBS에 희석해서 각 동물의 등쪽에 피하 주사하였습니다 (n=20). EF24는 디메틸술폰에 녹여서 염화나트륨으로 희석하였습니다. 주사 후 10일째에 EF24 처리된 쥐 (n=10)는 21일 동안 20 mg/kg/일의 농도로 200µL EF24를 복강 주사(i.p.)로 투여받았습니다. 대조 그룹 쥐 (n=10)는 매일 200µL PBS를 복강 주사로 투여받았습니다. 22일째에 종양을 제거해서 무게를 측정하였습니다. |
제형 | 20mg/kg; ip; 21 일 동안 |
응용 분야 | EF24는 피하HCC 종양 모델에서 종양 성장을 억제하고 세포 사멸을 유도합니다. |
References: | |
| Cas No. | 342808-40-6 | SDF | |
| Formula | C19H15F2NO | M.Wt | 311.33 |
| Solubility | Storage | Store at -20°C | |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.212 mL | 16.0601 mL | 32.1203 mL |
| 5 mM | 642.4 μL | 3.212 mL | 6.4241 mL |
| 10 mM | 321.2 μL | 1.606 mL | 3.212 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)















